"The shifts in the financial markets, international forces and the 2008 election will have enormous impact on the future of new technology in healthcare. The Medical Innovation Summit provides unrivaled insights, exceptional networking and actionable takeaways for anyone who cares about medical innovation."
- Tim Ring, CR Bard
CEOS of GE, Johnson & Johnson, Eli Lilly, Abbott, AstraZeneca, Amgen, Boston
Scientific, 3M, Medtronic and Edwards Lifesciences; partners from top venture
firms, heads of Government agencies and top clinicians.
IN MEMORIAM
Andrew C. Novick, MD
1948 - 2008
|
| Cleveland, Ohio | InterContinental Hotel & Bank of America Conference Center |
Past Summits
|
2004 LIST OF SPEAKERS:
- Olav B. Bergheim, General Partner,
Domain Associates
- Jim Broderick MD, General Partner,
Morgenthaler Ventures
- Jane L. Campbell, Mayor, City
of Cleveland
- Ken Charhut, President &
CEO, Orqis Medical
- Clayton M. Christensen, Robert
& Jane Cizik Professor of Business Administration, Harvard
Business School
- Delos M. Cosgrove, CEO and
President, CCF
- Michael J. Coyle, President,
St. Jude Medical, Cardiac Rhythm Management
- Lester M. Crawford DVM PhD,
Acting Commissioner, U.S. Food and Drug Administration
- Col. William C. DeVries MD,
Walter Reed Army Medical Center
- Ronald W. Dollens, President
& CEO, Guidant
- Dave Drachman, President &
CEO, AtriCure
- Juan Enriquez, Chairman &
CEO, Biotechonomy
- Mario J. Garcia MD, Cardiovascular
Medicine, CCF
- A. Marc Gillinov MD, Thoracic
& Cardiovascular Surgery, CCF
- Roy Greenberg MD, Vascular
Surgery, CCF
- William A. Hawkins III, President
& COO, Medtronic
- Guy J. LeBeau MD, Company Group
Chairman, Cordis
- P. Richard Lunsford, President
& CEO, Acorn Cardiovascular
- Bruce W. Lytle MD, Chairman
Dept. of Thoracic & Cardiovascular Surgery, CCF
- Mark Maciejewski, CEO, Symphony
Medical
- Mark B. McClellan MD PhD, Administrator,
Centers for Medicare & Medicaid Services
- Charles L. McIntosh MD PhD,
Chief Medical & Scientific Officer, Cook Group
- A. Malachi Mixon III, Chairman
& CEO, Invacare; Chairman of the Board of Trustees, CCF
- Michael A. Mussallem, Chairman
& CEO, Edwards Lifesciences Corporation
- Roger S. Newton PhD, Senior
Vice President, Esperion Therapeutics
- Steven S. Nissen MD, Cardiovascular
Medicine, CCF
- Kenneth Ouriel MD, Chairman
Division of Surgery, CCF
- Marc S. Penn MD PhD, Cardiovascular
Medicine, CCF
- Ferolyn Powell, CEO, Evalve
- Erich R. Reinhardt D.Eng, President
& CEO, Siemens Medical Solutions
- Timothy M. Ring, Chairman &
CEO, C.R. Bard
- Kevin Sharer, Chairman &
CEO, Amgen
- Nicholas G. Smedira MD, Thoracic
& Cardiovascular Surgery, CCF
- James M. Sweeney, Chairman
& CEO, Cardionet
- Bob Taft, Governor, State of
Ohio
- James R. Tobin, President &
CEO, Boston Scientific
- Eric J. Topol MD, Provost &
Chief Academic Officer, CCF; Chairman Dept. of Cardiovascular
Medicine, CCF
- Robert D. Walter, Founder,
Chairman & CEO, Cardinal Health
- Patrick L. Whitlow MD, Cardiovascular
Medicine, CCF
- Bruce L. Wilkoff MD, Cardiovascular
Medicine, CCF
- Jay S. Yadav MD, Cardiovascular
Medicine, CCF
2004 AGENDA:
| Monday, October 18, 2004 |
| 1:00 - 9:00 P.M. |
Registration |
| 4:00 - 4:15 P.M. |
Welcome
A. Malachi Mixon III
Chairman and CEO, Invacare;
Chairman of the Board of Trustees, The Cleveland Clinic
Foundation
Delos M. Cosgrove, M.D.
CEO and President, The Cleveland Clinic |
| 4:15 - 5:15 P.M. |
The AMGEN
Experience
Kevin Sharer
Chairman and CEO, AMGEN |
| 5:15 - 6:15 P.M. |
Taxus: How
do we get so lucky?
The Harder We Worked, the Luckier We Got!
James R. Tobin, Chairman and CEO, Boston Scientific
The unique challenges associated with the development of
combination drug/device technologies. The impact of approach,
infrastructure and mind set. Owning the organization strategy
of ‘not being first but being best’. |
| 6:30 - 10:30 P.M. |
Opening Reception, Dinner and Entertainment
Watch the Cleveland Cavaliers play the New Jersey Nets
at Gund Arena, followed by a reception with Cavaliers General
Manager Jim Paxson and select players and staff. |
Tuesday, October 19, 2004 |
| 6:30 A.M – 2:00 P.M. |
Registration |
| 7:00 – 8:00 A.M. |
Continental Breakfast |
| 8:00 - 8:20 A.M. |
The Honorable Bob Taft
Governor of Ohio
State of Cardiology
Eric J. Topol, M.D., Provost and Chief Academic Officer;
Chairman, Department of Cardiovascular Medicine, The Cleveland
Clinic
This address includes critical trends in cardiology, new
therapies, diagnostics and clinical approaches; and their
impact on per-patient expenses. |
| 8:20 – 9:50 A.M. |
Cardiovascular
Innovation in Action
Panel moderated by Eric J. Topol, M.D.:
Marc S. Penn, M.D., Ph.D., Director, Cardiac Intensive
Care Unit, CCF
Patrick L. Whitlow, M.D., Cardiovascular Medicine, CCF
Ferolyn Powell, CEO, Evalve
Bruce L. Wilkoff, M.D., Cardiovascular Medicine, CCF
Michael J. Coyle, President, St. Jude Medical CRMD
Mario J. Garcia, M.D., Cardiovascular Medicine, CCF |
| 9:50 – 10:20 A.M. |
Break |
| 10:20 – 11:00 A.M. |
A Case Study
in Cardiovascular Therapy
Steve S. Nissen, M.D., Cardiovascular Medicine, CCF
Roger S. Newton, Ph.D., CEO, Esperion |
| 11:00 – 11:50 A.M. |
Speeding Cardiovascular
Innovation in an Uncertain Environment
Guy J. Lebeau M.D., Company Group Chairman, Cordis
Jay S. Yadav, M.D., Department of Cardiovascular Medicine,
The Cleveland Clinic Foundation |
| 12:00 - 1:15 P.M. |
Lunch
The Honorable Jane L. Campbell, Mayor
The City of Cleveland, Ohio
A Policy Environment
that Encourages Medical Innovation
Ronald W. Dollens, President and CEO, Guidant
How do today’s health policies both encourage and
discourage medical innovation. |
| 1:15 – 2:10 P.M. |
Lessons in
Innovation: A Case Study in Heart Failure
William A. Hawkins III, President and COO, Medtronic |
| 2:10 – 2:25 P.M. |
The State
of Cardiac Surgery
Bruce W. Lytle, M.D., Chairman, Department of Thoracic
& Cardiovascular Surgery, The Cleveland Clinic |
| 2:25 – 3:25 P.M. |
Surgical Innovation
in Action
Panel moderated by Bruce W. Lytle, M.D.:
Marc Gillinov, M.D., Thoracic and Cardiovascular Surgery,
CCF
Dave Drachman, President and CEO, AtriCure
Nick G. Smedira, M.D., Thoracic and Cardiovascular Surgery,
CCF
P. Richard Lunsford, President and CEO, Acorn Cardiovascular
Roy Greenberg, M.D., Vascular Surgery, CCF
Charles McIntosh, M.D., Ph.D., CTO, Cook Group |
| 3:25 – 3:55 P.M. |
Break |
| 3:55 - 4:30 P.M. |
The Biomedical
Century: New Technology, New Evidence, New Costs
Mark B. McClellan, M.D., Ph.D. , Administrator, Center
for Medicare and Medicaid Services, Department of Health
and Human Services
New scientific approaches allow for more individualized,
effective treatments based on a fundamental understanding
of how diseases affect individual patients. The challenge
of making health care decisions based on sound evidence
of benefits and costs for individual patients may determine
whether we realize the potential for better medical care
in the 21st century. |
| 4:30 – 5:10 P.M. |
Cardiovascular
Innovation in International Markets: Challenges and Opportunities
Michael A. Mussallem, Chairman and CEO, Edwards Lifesciences
Corporation
While cardiovascular disease is projected to remain the
leading cause of death in the world for decades to come,
investment in cardiovascular care varies widely around the
globe. Mr. Mussallem will discuss the environmental and
cultural factors required for successful cardiovascular
innovation, as well as the potential for disruptive technologies
to serve the growing, high-need patient population. |
| 5:10 - 5:50 P.M. |
Fostering
Innovation Through Integration
Robert D. Walter, Founder, Chairman and CEO, Cardinal Health
The pace of innovation and need to continually serve customers
is unyielding in the $4 trillion global healthcare market.
Cardinal Health has quietly built its business by fostering
a culture that thrives on the rate of change in healthcare,
rapidly adding new products and services, acquiring new
capabilities and innovating in strategic areas of process,
technology and service delivery. In his presentation, Robert
D. Walter provides examples and discusses the lessons he
has learned that have enabled Cardinal Health to become
the preeminent ‘healthcare to healthcare’ provider
in this vast marketplace. |
| 6:00 – 7:00 P.M. |
Welcome Reception
Hosted by Squire, Sanders & Dempsey, LLP |
| 7:00 P.M. |
Dinner
Remaking Health
Care Innovation
Clayton M. Christensen, Robert and Jane Cizik Professor
of Business Administration, Harvard Business School |
Wednesday, October 20, 2004 |
| 6:30 – 9:00 A.M. |
Registration |
| 6:30 – 7:30 A.M. |
Continental Breakfast |
| 7:30 - 9:00 A.M. |
Live Surgery
Moderated by Kenneth Ouriel, M.D.,
Chairman, Division of Surgery, The Cleveland Clinic
Innovation in Practice: Side-by-Side Comparison
of Traditional Surgeries with New Minimally Invasive Counterparts
|
| 9:00 – 9:45 A.M. |
Juan Enriquez
Chairman and CEO, Biotechonomy |
| 9:45 - 10:15 A.M. |
Break |
| 10:15 - 11:00 A.M. |
Success in
the Midst of Savage Competition
Timothy M. Ring, President and CEO, C.R. Bard |
| 11:00 - 12:00 P.M. |
The Challenge
in the Commercialization of Cardiovascular Technology
Panel moderated by Harry T. Rein, General Partner
Foundation Medical Partners and includes:
Olav B. Bergheim, General Partner, Domain Associates
Jim Broderick, M.D., General Partner, Morgenthaler Ventures
Mark Maciejewski, CEO, Symphony Medical
Jim M. Sweeney, CEO, Cardionet
Ken Charhut, President and CEO, Orqis |
| 12:15 – 1:15 P.M. |
Lunch
FDA’s
Initiatives to Stimulate Medical Innovation
Lester M. Crawford, D.V.M., Ph.D. Acting Commissioner U.S.
Food and Drug Administration
Dr. Crawford addresses the agency’s recent efforts
to encourage new drug and device development and manufacturing
through regulation reform and by identifying and addressing
hazards that cause the failure of candidate drugs/devices
to demonstrate safety and effectiveness. |
| 1:15 – 2:00 P.M. |
New Imaging
Technologies and Impact in Underlying Economics
Erich R. Reinhardt, D.Eng.
Group President and CEO, Siemens Medical Solutions
Many innovative technologies, for example CT and MR, have
emerged in the past few decades. These technologies have
fundamentally changed medical diagnostics and helped to
increase the quality of healthcare and reduce its cost.
Mr. Reinhardt will focus on the potential for innovation
in diagnostic and therapeutic technologies to continue to
improve healthcare efficiency, and especially address the
promising role of molecular medicine. |
| 2:00 – 2:45 P.M. |
Regulatory
Approval: A Case Study with an Historical Perspective
Col. William C. DeVries, M.D.
Walter Reed Army Medical Center |
| 3:00 – 3:30 P.M. |
Wrap Up |
|
|
|
